Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Nivolumab |
Indication/Tumor Type | lung non-squamous non-small cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung non-squamous non-small cell carcinoma | sensitive | Nivolumab | Phase III | Actionable | In a Phase III trial (CheckMate 057), Opdivo (nivolumab) treatment demonstrated greater overall survival, progression-free survival, and objective response rate at all CD274 (PD-L1) expression levels analyzed (1% or more, 5% or more, 10% and more) in nonsquamous non-small cell lung carcinoma patients (PMID: 26412456; NCT01673867). | 26412456 |
PubMed Id | Reference Title | Details |
---|---|---|
(26412456) | Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. | Full reference... |